The binary catalyst is LUGANO Phase 3 topline data in August 2026. Earnings are non-events for this pre-revenue biotech. Position for volatility around the readout, which will determine DURAVYU's commercial viability in wet AMD. DME data (Q4 2027) is a longer-term driver.
Price Chart
Executive Summary
EyePoint reported Q2 2026 revenue of $0.5M (consensus $372K) and EPS of -$1.09 (consensus -$0.96, miss of 13.5%). The headline financials reflect a pre-revenue clinical-stage biotech burning cash on Phase 3 trials. The key news is that LUGANO topline wet AMD data is expected imminently in August 2026, with LUCIA in Q4 2026, and DME trials fully enrolled. The company skipped the earnings call due to the upcoming catalyst. Cash runway extends into Q4 2027.
Key Financial Metrics
Key Facts
- Q2 2026 total net revenue $0.5M vs $5.3M in Q2 2025, driven by deferred revenue recognition from 2023 YUTIQ license agreement
- Net loss $94.5M (-$1.09/share) vs $59.4M (-$0.85/share) in Q2 2025, reflecting higher R&D spend on Phase 3 trials
- Cash, cash equivalents, and marketable securities $180M as of June 30, 2026, down from $223M at March 31, 2026
- Phase 3 wet AMD trial LUGANO topline data expected in August 2026; LUCIA topline data in Q4 2026
- Phase 3 DME trials COMO and CAPRI fully enrolled (over 480 patients in 5 months), topline data anticipated Q4 2027
- Positive DSMC recommendation for LUGANO/LUCIA in May 2026, no safety concerns
- No earnings conference call held due to upcoming LUGANO data readout
- Tarek S. Hassan, M.D., appointed Chief Strategic Science Officer in July 2026
Financial Impact
Q2 2026 revenue $0.5M (90.6% YoY decline from $5.3M); net loss $94.5M (-$1.09/share) vs consensus -$0.96. Cash burn of $43M in Q2 2026.
Risk Factors
- LUGANO/LUCIA Phase 3 trial results could miss non-inferiority or safety endpoints, leading to stock decline
- Cash runway into Q4 2027 may require additional financing if trials extend or if approval costs arise
- FDA regulatory uncertainty and warning letter on Watertown facility remain unresolved
- No approved products as a commercial-stage biotech; stock is a binary bet on DURAVYU approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333821 |
| Document: eypt-20260805.htm | 0001193125-26-333821 |
| Document: eypt-ex99_2.htm | 0001193125-26-333821 |
| Document: 0001193125-26-333821-index-headers.html | 0001193125-26-333821 |
| Document: 0001193125-26-333821-index.html | 0001193125-26-333821 |
| Document: 0001193125-26-333821.txt | 0001193125-26-333821 |
| 8-K Data (Synthetic) | 0001193125-26-333821 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | 8-K | $0.4400 $0.3707 | ▲ +15.75% | ▲ +15.61% | $0.3700 (+15.91%) |
Oct 19, 2026 7d ago | Press Release | $0.4400 $0.3657 | ▲ +16.89% | ▲ +16.74% | $0.3700 (+15.91%) |
Oct 7, 2026 19d ago | SC 13G/A | $3.32 $3.01 | ▼ −9.34% | ▼ −8.36% | $0.3700 (−88.86%) |
Sep 10, 2026 6w ago | 8-K | $4.25 $3.99 | ▼ −6.12% | ▼ −5.62% | $0.3700 (−91.29%) |
Aug 18, 2026 9w ago | Insider Buy | $6.30 $4.99 | ▼ −20.79% | ▼ −20.41% | $0.3700 (−94.13%) |
Aug 17, 2026 10w ago | 8-K | $4.87 $4.87 | · 0.00% | ▲ +1.19% | $0.3700 (−92.40%) |
Aug 5, 2026 11w ago | 8-K | $12.25 $13.53 | ▲ +10.45% | ▲ +10.10% | $0.3700 (−96.98%) |
Jul 30, 2026 12w ago | 8-K | $12.86 $12.83 | ▼ −0.23% | ▼ −3.86% | $0.3700 (−97.12%) |
Jun 22, 2026 18w ago | 8-K | $13.73 $14.11 | ▲ +2.77% | ▲ +3.22% | $0.3700 (−97.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers